Clinical Trial Update: A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating LX211 for non-infectious uveitis has completed. The study examined posterior, intermediate, and pan-uveitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panuveitis
• Uveitis Intermediate
• Uveitis Posterior

Drugs mentioned

• LX211

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Status: COMPLETED